Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA101 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
**IMA101 + atezolizumab** is a combination therapy investigated for advanced relapsed and/or refractory solid tumors in HLA-A*02:01-positive patients. IMA101 is an autologous, multi-target adoptive T cell therapy: patients’ T cells are isolated, primed, and expanded ex vivo against multiple tumor-associated peptide-HLA cancer antigens (including PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and MMP1), then infused following lymphodepleting chemotherapy and low-dose interleukin-2. Atezolizumab (a monoclonal antibody against PD-L1) is administered to block checkpoint inhibition, potentially reducing intratumoral T cell suppression. This approach aims for synergism—direct tumor cytotoxicity by targeted T cells combined with immune checkpoint inhibition to improve persistence and response rates. The main developer for IMA101 is Immatics; atezolizumab is developed by Genentech/Roche. Primary indication investigated is advanced solid cancers. No objective clinical responses have yet been reported in early-stage trials; safety and feasibility are demonstrated[1][2][4].
- Other names
- IMA101 + atezolizumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)pHLA-A*02:01 (Patient-specific tumor-associated peptide–HLA-A*02:01 complex)
Beyond the preview
Go deeper on IMA101 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA101 + atezolizumab.